Abstract
Fabry disease (FD) is an X-linked inborn error of glycosphingolipid (GSL) metabolism, caused by a deficiency of the lysosomal α-galactosidase A, which results in high levels in lysosomes and biological fluids of globotriaosylceramide (Gb3) and digalactosylceramide (Ga2), also known as galabiosylceramide. We report here a detailed study of the molecular species of GSLs in urinary samples obtained from hemizygous and heterozygous patients by use of matrix-assisted laser desorption ionisation and tandem mass spectrometry (MALDI–MS–MS). Twenty-two and fifteen molecular species were identified in the globotriaosylceramide and digalabiosylceramide series, respectively. The major sphingoid base was sphingosine (d18:1), and dihydrosphingosine (C18:0) and sphingadienine (d18:2) were also present. The molecular profiles obtained by MALDI–TOF-MS enabled us to show significant differences between GSLs composition for young, adult or atypic hemizygote and heterozygote patients. Thus, MALDI–TOF-MS and MS–MS proved a powerful tool for screening a population of patients with clinical signs suggestive of FD by direct and rapid GSL fingerprinting and identification, and for study of the biological processes occurring in glycosphingolipid accumulation.
Similar content being viewed by others
References
Desnick RJ, Sweeley CC, Krivit W (1970) J Lipid Res 11:31–37
Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) N Engl J Med 276:1163–1167
Germain DP, Benistan K, Boutouyrie P, Mutschler C (2005) Clin Gen (in press)
Lyon MF (1961) Nature 190:372–373
Shoichiro N, Toshihiro T, Maeda M, Chihaya K, Akihiro T, Minoru T, Aichi Y, Masaru K, Hidemasa H, Hitoshi S, Hiromitsu T (1995) N Engl J Med 333:288–293
Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ (2003) Kidney Int 64:801–807
Bach G, Roenmann E, Karni A, Cohen T (1982) Clin Gen 21:59–64
Vance DE, Krivit W, Sweeley CS (1969) J Lipid Res 10:188–192
Schibanoff JM, Kamoshita S, O’Brien JS (1969) J Lipid Res 10:515–520
Roy S, Gaudin K, Germain DP, Baillet A, Prognon P, Chaminade P (2004) J Chromatogr B 805:331–337
Ullman MD, McCluer RH (1977) J Lipid Res 18:371–378
Gross SK, McCluer RH (1979) Anal Biochem 102:429–433
Ullman MD, Pyeritz RE, Moser HW, Wenger DA, Lolodny EH (1980) Clin Chem 26:1499–1503
Zeidner KM, Desnick RJ, Ioannou YA (1999) Anal Biochem 267:104–113
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linhorst GE, Desnick RJ (2001) N Engl J Med 345:9–16
Vance DE, Swelley CC (1967) J Lipid Res 8:621–630
Karas M, Bachmann D, Bahr U, Hillenkamp F (1987) Int J Mass Spectrom Ion Processes 78:53–68
Boscaro F, Pieraccini G, la Marca G, Bartolucci G, Luceri C, Luceri F, Moneti G (2002) Rapid Commun Mass Spectrom 16:1507–1514
Nelson BC, Roddy T, Araghi S, Wilkens D, Thomas JJ, Zhang K, Sung C, Richards SM (2004) J Chromatogr B 807:127–134
Mills K, Johnson A, Winchester B (2002) FEBS 515:171–176
Schiller J, Arnhold J, Benard S, Müller M, Reichl S, Arnold K (1999) Anal Biochem 267:6–56
Hunnam V, Harvey DJ, Priestman D, Bateman RH, Bordoli RS, Tyldesley R (2001) J Am Soc Mass Spectrom 12:1220–1225
Folch J, Lees M, Sloane Stanley GH (1957) J Biol Chem 226:497–509
Karas M, Hillenkamp F (1988) Anal Chem 60:2299–301
Olling A, Breimer ME, Peltomaa E, Samuelson BE, Ghardashkhani S (1998) Rapid Commun Mass Spectrom 12:637–645
Olsson B-M, Karlsson H, Larsson T, Lanne B (1999) J Mass Spectrom 34:942–951
Levery SB, Toledo MS, Doong RL Straus AH, Takahashi HK (2000) Rapid Commun Mass Spectrom 14:551–563
Hsu FF, Turk J (2001) J Am Soc Mass Spectrom 12:61–79
Costello CE, Vath JE (1990) Methods Enzymol 193:738–768
Ann Q, Adams J (1993) Anal Chem 65:7–13
Takakuwa N, Kinoshita M, Oda Y, Ohnishi M (2002) FEMS Yeast Res 2:533–538
Imai H, Morimoto Y, Tamura K (2000) J Plant Physiol 157:453–456
Renkonen O, Hirvisalo EL (1982) J Lipid Res 10:687–693
Ando S, Isobe M, Nagai Y (1976) Biochim Biophys Acta 424:98–105
Colsch B., Afonso C, Popa I, Portoukalian J, Fournier F, Tabet JC, Baumann N (2004) J Lipid Res 45:281–286
Cable WJL, McCluer RH, Kolodny EH, Ullman MD (1982) Neurology 32:1139–1145
Fogazzi GB, Garigali G (2003) Curr Opin Nephrol Hypertens 12:625–632
Germain DP (2002) Expert Opin Investig Drugs 11:1467–1476
Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) J Am Med Assoc 285:2743–2749
Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP and International Fabry Disease Study Group (2004) Am J Hum Genet 75:65–74
Acknowledgements
D.T. is indebted to the Institut de Chimie des Substances Naturelles (CNRS) for a PhD research fellowship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Touboul, D., Roy, S., Germain, D.P. et al. Fast fingerprinting by MALDI–TOF mass spectrometry of urinary sediment glycosphingolipids in Fabry disease. Anal Bioanal Chem 382, 1209–1216 (2005). https://doi.org/10.1007/s00216-005-3239-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-005-3239-8